Basf Se Corporation

Felicitas Guth

Karl Kolter

Maximilian Angel

Michael Schönherr

Bernhard Fussnegger

Bastiaan Bram Pieter Staal

Theo Smit

Frank Schmidt

Silke Gebert

Franz Weber

Matthias Karl

Michael Klemens Müller

Maximilian Blochberger-Claus

Ferdinand Paul Brandl

Heiko Alexander Schiffter

Pedro Sa Gomes

Nigel A Langley

Terpolymer, wherein 20 to 35% by weight of the structural units are derived from acrylic acid, 45 to 60% by weight of the structural units from a hydrophobic methacrylate selected from a group consisting of isopropyl methacrylate, tert-butyl methacrylate and cyclohexyl methacrylate and 15 to 40% by weight of the structural units from a third olefinic monomer selected from the group consisting of N-vinyl lactam, hydroxy ethyl methacrylate and phenoxyethyl acrylate with the proviso that the total amount of structural units derived from the three monomer groups adds up to 100% by weight, and the use of the terpolymers as crystallization inhibitors in pharmaceutical dosage forms for inhibiting the recrystallization in an aqueous environment of a human or animal body of an active ingredient.

Terpolymers and their use in pharmaceutical dosage forms

The use of powder-form, crosslinked, water-insoluble, low-swelling polyacrylates as disintegrants for solid pharmaceutical dosage forms.

Poly(meth)acrylic acid popcorn polymerizates as disintegrants for tablets

A finely divided binder in powder form consisting of a polyethylene glycol-polyvinyl alcohol graft polymer particles, wherein the particles have an average particle size D[4,3] in the range of from 10 to 70 &#x3bc;m.

Dry-binders for tablets based on polyethylene glycol-polyvinyl alcohol graft polymers, the production and use thereof

Water-soluble polymeric salts of medicaments sparingly soluble in water consisting of a cationogenic medicament which, in uncharged form or as hydrochloride, has a solubility of less than 0.1% (m/m) in water, artificial intestinal juice or gastric juice, and an anionogenic water-soluble polymer having a solubility in water of at least 5% (m/m) in the pH range of 1 to 13 and which is obtained by free-radically initiated polymerization of a monomer mixture of i) 70 to 90% by weight N-vinylpyrrolidone and ii) 10 to 30% by weight acrylic acid, wherein the sum total of i) and ii) corresponds to 100% by weight.

Salts of active ingredients with polymeric counterions

Described is a storage-stable dust-free homogeneous particulate formulation. The formulation consists of (a) at least one water-soluble Vitamin E-derivative, (b) at least one hydrophilic polymer, (c) optionally additional surface-active substances, and (d) optionally additional pharmaceutical additives. The sum of (a), (b), (c) and (d) equals 100% by weight of the formulation. The fines fraction with particle diameters of less than 100 &#x3bc;m is less than 10% by weight. Describe also is a process for manufacturing the formulation, and use of the formulation as a solubilizing composition in pharmaceutical formulations.

Storage-stable dust-free homogeneous particulate formulation

A storage-stable dust-free homogeneous particulate formulation comprising at least one water-soluble Vitamin E-derivative and at least one hydrophilic polymer. In one embodiment the storage-stable dust-free homogeneous particle formulation, consists of Methods of making the particulate formulation by a spray granulation process are also provided.

Storage-stable dust-free homogeneous particulate formulation comprising at least one water-soluble vitamin E-derivative and at least one hydrophilic polymer

Growing community of inventors

Neustadt, Germany

Felicitas Guth